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Antimicrobial resistance (AMR) has become a global public health concern threatening current 
effective prevention and treatment options. Infections caused by antimicrobial resistance 
strains are costly, often harder to treat and sometimes fatal. One group of bacteria that 
contributes to AMR are the extended beta lactamase (ESBL) and AmpC beta lactamase 
(AmpC) producing E. coli. These are on the critical list of important antibiotic-resistant bacteria 
of human importance compiled by the World Health Organisation and are a public health 
concern due to their resistance to an extended range of beta lactams.  
The main driver for the spread of AMR is the use of antimicrobials in both human and animals. 
One potential spread is by the feeding of waste milk to calves. Waste milk is the milk that 
contains antibiotics or other drugs. Waste milk is not recommended as feed for calves due to 
its association with the development of antibiotic resistance bacteria. 
Using the culture depended methods and whole genome sequencing, this study aimed to 
determine the prevalence of ESBL and AmpC producing E. coli isolated from recto-anal 
mucosal swabs (RAMS) from waste milk fed dairy calves, and to phenotypically and 
genotypically characterise ESBL and AmpC producing isolates.  Recto-anal mucosal swabs 
samples (n = 40) from waste milk fed dairy calves collected from Canterbury region, New 
Zealand were screened for antimicrobial resistant E. coli. 
Fifty-eight percent (23/40) of the calves harboured antibiotic resistant E. coli. 25% (10/40) 
calves were positive for AmpC producing E. coli and none of the calves were positive for ESBL 
producing E. coli. The highest prevalence of resistance was observed for tetracycline. PCR and 
Sanger sequencing revealed that all the AmpC positive E. coli were chromosomal mediated 
with four mutations in the promoter region of the ampC gene. Whole genome sequencing of 
eight isolates resistant to both tetracycline and streptomycin revealed additional resistance 
genes that were not tested phenotypically. Using the Clermont phylogrouping method of E. 
coli, the AmpC positive, the tetracycline and streptomycin resistant E. coli isolates were 
distributed among phylogroups B1, C and D. 
In conclusion, this study revealed the presence of AmpC producing E. coli and other resistance 
genes in E. coli isolated from waste milk fed calves. Further epidemiological studies are 
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1 Literature review 
1.1 Introduction 
Antimicrobial resistance (AMR) has become a global public health concern threatening current 
effective prevention and treatment options. Infections caused by AMR strains are costly, often 
harder to treat and more likely to have fatal outcomes (WHO, 2014). In Europe, a joint report 
by the European Centre for Disease Prevention and Control (ECDC) and the European 
Medicines Agency  (EMA) estimated that annually there are approximately 25 000 deaths and 
a €1.5 billion cost, associated with infection caused by antibiotic resistant bacteria (ARB) 
(ECDC & EMA, 2009). In addition, in 2015, it was estimated that in the European Union, 671 
689 (95% uncertainty interval [UI] 583 148–763 966) infections were due to antibiotic 
resistance bacteria and these contributed to 33 110 (28 480–38 430) attributable deaths (Cassini 
et al., 2019). In USA, a report from Centres for Disease Control (CDC) estimated that 
approximately 2 million people suffer from infections caused by ARB, leading to not less than 
23,000 deaths every year, with an estimated annual cost of US$ 55 Billion for hospital care and 
production losses (CDC, 2013; Prestinaci et al., 2015). There is limited accurate and reliable 
data on AMR in most African countries even though AMR occurs and deaths due to infections 
caused by ARB have been documented in some countries such as Kenya, Uganda, South 
Africa, Egypt, Tanzania and Rwanda (Ampaire et al., 2016; Kimang’a, 2012; B. T. Tadesse et 
al., 2017). On the other hand, New Zealand had low rates of AMR. However, the situation has 
considerably changed over the past two decades, with the emergence and spread of antibiotic 
resistance pathogens such as the extended-spectrum β-lactamase-producing Enterobacteriaceae 
due to overuse of antimicrobials, importation of ARB from antibiotic resistance endemic areas 
and spreading of ARB from hospital settings to the communities (Thomas et al., 2014; 
Williamson & Heffernan, 2014). 
The development of resistance in bacteria has been associated with the use of antimicrobials in 
both human and animal health settings  (Holmes et al., 2016). In addition, exposure to heavy 
metals, biocides and disinfectants may also contribute to AMR (Berendonk et al., 2015; Horner 
et al., 2012). However, resistance mechanisms also occur naturally and without external forces 
in bacteria facilitating adaptation for their survival (Etebu & Ukpong, 2016; Holmes et al., 
2016). Resistance develops either through inherent or acquired mechanisms with the latter 
being the major concern as multiple resistance genes can be transferred from one bacteria cell 
to the other (Levin & Rozen, 2006). Bacterial resistance mechanisms include; 1) efflux pumps, 
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2) modification of cellular targets, 3) inactivation of enzymes, 4) overproduction of enzymes 
and 5) triggering of an alternative pathway that bypasses the drug action (Alekshun & Levy, 
2007; Christaki et al., 2020; Tenover, 2006).  
One bacterial group that contributes to AMR are the extended-spectrum β-lactamase producing 
Enterobacteriaceae (ESBL-E) and AmpC β-lactamase producing Enterobacteriaceae (AmpC-
E). The ESBL and AmpC β-lactamases confer resistance by means of inactivation of enzymes. 
ESBL-E are resistant to β-lactam antibiotics including the first, third and some fourth 
generation cephalosporins, as well as monobactams. AmpC-E are resistant to cephamycins ( 
second generation cephalosporins) in addition to the above antibiotics but not resistance to the 
fourth generation cephalosporins (Ewers et al., 2012; Pfaller & Segreti, 2006). Their resistance 
to a wide range of commonly used antibiotics is worrisome and has complicated treatment 
options in hospitalised patients in both humans and animals. 
1.2 Escherichia coli: the bacterial pathogen 
Escherichia coli is a gram-negative bacteria belonging to the Enterobacteriaceae family 
(Croxen et al., 2013; Lukjancenko et al., 2010). E. coli is part of the normal microflora of the 
gastrointestinal tract of warm-blooded animals, including humans, and may persist in the 
environment (Van Elsas et al., 2011). However, gene gain and loss has led to increased 
pathogenicity of certain strains of E. coli, causing serious illness in humans and animals 
worldwide (Kaper et al., 2004). E. coli can be classified in multiple ways according to, 1) 
pathogenicity, there is pathogenic and non-pathogenic E. coli, 2) site of infection or clinical 
manifestations in humans, such as enteropathogenic or uropathogenic pathotypes, and 3) 
virulence mechanism, for instance enterohaemorrhagic E. coli (EHEC) or enterotoxigenic 
E. coli (ETEC). Traditionally, E. coli have also been serotyped based on the somatic (O) and 
flagella (H) antigens. Another commonly used method is multilocus sequence typing (MLST) 
using the concatenated sequence of seven housekeeping genes adk, fumC, gyrB, icd, mdh, purA, 
and recA (Kaper et al., 2004; Lukjancenko et al., 2010; Wirth et al., 2006).  
As a population (pathogenic and non-pathogenic), E. coli isolates can be assigned into 7 
phylogroups: A, B1, B2, C, D, E and F through a multiplex PCR process described by Clermont 
et al. (2013). Most commensal isolates belong to phylogroup A or B1, while extraintestinal 
isolates mainly belong to group B2 or D. Various studies have reported group A and B1 being 
the most common in calves, while B2 is commonly found in humans. (Barzan et al., 2017; 
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Escobar et al., 2006; Johnson et al., 2003; Johnson et al., 2002). However, it should be noted 
that an E. coli pathotype may be represented by more than one phylogroup. 
ESBL/AmpC producing E. coli are on the critical list of important antibiotic-resistant bacteria 
compiled by WHO. This priority list of 20 bacteria of human importance was compiled using 
ten criteria related to health and antibiotic resistance such as mortality and prevalence of 
resistance respectively, categorising bacteria as critical, high or medium importance 
(Tacconelli et al., 2018). Antibiotic resistant ESBL/AmpC producing E. coli has been reported 
in both humans and animals worldwide (Ahmed et al., 2009; Gagliotti et al., 2011; Khachatryan 
et al., 2004; Okeke et al., 2005; D. A. Tadesse et al., 2012; Vieira et al., 2011) 
Horizontal gene transfer (HGT) is an important evolutionally force in the survival of bacteria 
(Soucy et al., 2015). HGT can occur through transformation, transduction and conjugation. The 
loss or gain of new mobile genetic elements has a pivotal role in the survival of pathogenic 
bacteria in a hostile environment. Mobile genetic elements include transposons, integrons, and 
insertion sequence common region (ISCR) elements. This method is important as many new 
traits, including antimicrobial resistance genes are transferred between various strains of E. coli 
using this mechanism (Christaki et al., 2020; von Wintersdorff et al., 2016). 
1.3 Beta lactamases 
E. coli, previously called Bacillus coli, was the first organism to be associated with the 
production of β-lactamase enzymes (Abraham & Chain, 1940). Since then, the production of 
β-lactamase enzymes has been the most common resistant mechanism observed in gram-
negative bacteria (Bush, 2018). These enzymes protect the bacteria by inactivating β-lactam 
antibiotics through a hydrolysis reaction (Zeng & Lin, 2013). However, the resistance of these 
β-lactamase enzymes can be inhibited by β-lactamase inhibitors, such as clavulanic acid, 
tazobactam, avibactam and sulbactam (Bush, 2018; Drawz & Bonomo, 2010). β-lactamases 
have been classified based on two major schemes. The Ambler classification scheme (A to D) 
is based on amino acid sequence (Ambler, 1980), while the Bush-Jacoby-Medeiros scheme (1 
to 4) is based on molecular structure and later changed to substrate and inhibitors profiles (Bush 
et al., 1995) (Table 1).
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Table 1. Important β-lactamase enzymes of E. coli and the affected β-lactam antibiotics (Drawz & Bonomo, 2010; Olsen, 2015)






A 2b Penicillinases, narrow 
spectrum β-lactamase 
(NSBL)  
TEM-1, SHV-1 (parent 
enzymes), TEM-2 




Mutated variants of SHV-1, 
TEM-1, CTX-Ms 
Clavulanate Penicillin, cephalosporins1, monobactams 





Metallo β- lactamases 
carbapenamase 
 
IMP-1, VIM-1, NDM EDTA, 
dipicolinic 
acid 














Penicillin, cephalosporins, monobactams 
cephamycin except carbapenems 
CMY, FOX, ACC, LAT 
MIR, ACT, MOX, DHA 




Penicillin, cephalosporins, monobactams 
cephamycin except carbapenems 
D 
 
2d Oxacillinases OXA NaCl Penicillin, cephalosporins, carbapenems, 
monobactams  
1 cephalosporins 1st, 2nd, 3rd and 4th generation  
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1.4 Extended Spectrum β-lactamase enzymes (ESBL) 
Extended Spectrum β-lactamase enzymes (ESBL) are a class of β-lactamases that confer 
bacterial resistance to penicillins, cephalosporins and monobactams but not cephamycins and 
carbapenems. ESBL can be inhibited by clavulanic acid (Bradford, 2001; Paterson & Bonomo, 
2005; Pitout & Laupland, 2008). In the 1960s increased bacterial resistance to penicillin and 
1st generation cephalosporins due to penicillinase and ampicillin hydrolysing β-lactamase, led 
to the discovery of 3rd generation cephalosporins and other oxyimino-cephalosporins in 1980s, 
that were stable in the presence of these β-lactamases. However, that stability did not last long, 
as resistance was discovered in the 3rd generation cephalosporins and the oxyimino 
cephalosporins due to their overuse and mutation was observed on the parent enzyme (TEM-1 
and SHV-1) (Paterson & Bonomo, 2005). TEM-1 (based on patient name Temoniera) from E. 
coli  and SHV-1 (sulfhydryl variable) from Klebsiella pneumoniae and E. coli (Datta & 
Kontomichalou, 1965; Philippon et al., 1989) are parent ESBL enzyme types and are plasmid 
mediated.  The first ESBL enzyme type was reported in 1983 from a German patient and the 
encoding gene indicated there was a mutation of the parent enzyme SHV-1. Other β-lactamases 
were later discovered that were closely related to TEM-1 and TEM-2 and conferred  resistance 
to 3rd generation cephalosporins (Knothe et al., 1983). These are called extended spectrum β-
lactamase enzymes due to their expanded ways of hydrolysing a wider range of β-lactams, 
including 3rd generation cephalosporins, penicillin and 1st generation cephalosporins. To date 
there are at least 167 TEM and 132 SHIV β-lactamase types that have emerged globally due to 
mutation of the parent enzyme TEM-1 and SHV-1 http://www.laced.uni-stuttgart.de/. 
CTX-M (based on greater hydrolytic activity against cefotaxime than ceftazidime) is an ESBL 
enzyme type that has emerged as a result of horizontal gene transfer, probably from a 
chromosomally encoded β-lactamase gene of Kluyvera spp. (Bonnet, 2004; Humeniuk et al., 
2002). CTX-M types have been the most common ESBL enzymes reported globally and there 
are over 172 CTX-M enzymes classified into 5 clusters (CTX-M-1, CTX-M-2, CTX-M-8, 
CTX-M-9, and CTX-M-25) (Ramadan et al., 2019). In humans the most common variant 
reported is CTX-M-15, which belongs to cluster CTX-M-1, followed by CTX-M-14 which 
belongs to the CTX-M-9 group (Iovleva & Bonomo, 2017; Saravanan et al., 2018). In livestock 
CTX-M-1, is the most prevalent, followed by CTX-M-15 and CTX-M-14 (Table 2). Other 




1.5 AmpC β-lactamase 
In contrast to ESBLs as described in the previous section, AmpC can hydrolyse cephamycins 
such as cefoxitin and cefotetan, in addition to the penicillin, cephalosporins and monobactams 
and are not inhibited by clavulanic acid (Jacoby, 2009). Genes expressing ampicillin 
hydrolysing β-lactamase enzyme (AmpC β-lactamase) can be found either on the bacterial 
chromosome or plasmid.  These cannot be differentiated phenotypically but rather through 
multiplex and promoter polymerase chain reaction (PCR) (Pérez-Pérez & Hanson, 2002). 
Chromosomal AmpC, from E. coli, was the first bacterial enzyme recorded to destroy penicillin  
(Abraham & Chain, 1940). The first plasmid mediated AmpC was reported in 1989 in K. 
pneumoniae, with an enzyme type designated as CMY-1 (based on greater activity on 
cephamycin) (Philippon et al., 2002). Currently over 139 variants of CMY have been reported 
worldwide (Bush, 2018). Plasmid mediated AmpC have been found in both nosocomial and 
community isolates around the world. Apart from CMY, other important enzyme varieties 
including FOX, ACC, LAT, MIR, ACT, MOX, DHA, CFE (Figure 1) have also been reported 
although CMY is the most prevalent (Jacoby, 2009). 
Expression of the chromosomal gene ampC is low in many Enterobacteriaceae but can be 
overexpressed when exposed to β-lactams (Jacoby, 2009). This process is induced by the action 
of the ampC genes ampD, ampG, ampR, and intermediates in peptidoglycan recycling. This 
process does not occur in E. coli as it lacks the ampR gene. However, expression of ampC and 
overproduction can still occur after mutation in the promoter or attenuator region (Philippon et 
al., 2002). It has been observed that overproduction of chromosomal AmpC occurs most in 















Figure 1. Reporting timeline of important ESBLs and AmpC β-lactamase evolution in E. coli, CMY, CFE are AmpC enzymes while TEM, SHV 
OXA and CTX-M are ESBL. 










1.6 ESBL/AmpC producing E. coli in New Zealand 
The prevalence of human infections associated with ESBL-E/AmpC producing E. coli has 
increased rapidly in recent years in New Zealand (Dyet et al., 2014; Thomas et al., 2014). 
National annual surveys conducted by the Institute of Environmental Science and Research 
Limited (ESR) since 2005 has reported an increase in the prevalence of ESBL/AmpC 
producing E. coli. Results from a 2006-2008 survey, showed that about 2.6% of E. coli from 
community and hospital-based isolates were ESBL positive, while 3.8% was recorded in 2009-
2011, a 46% increase (Heffernan et al., 2013). By 2016, there was a national average prevalence 
rate of 11.1 per 100 000 population, from whom ESBL producing Enterobacteria were isolated, 
based on clinical samples. E. coli was more prevalent 74.1% (386/521) than other 
Enterobacteriaceae species and  The Manukau Counties District Health Board registered the 
highest prevalence rate of 21.3 people per 100 000 (Heffernan et al., 2018). Furthermore, in 
2012 it was reported that about 4000 people had suffered infections caused by ESBL producing 
pathogens with E.coli being the main cause (Thomas et al., 2014).  
In New Zealand human clinical studies of ESBL-E isolates, the most predominant ESBL genes 
are blaCTX-M-15 and blaCTX-M-14. In a 2006 study of human urine samples (community-acquired), 
it was found that the most common enzyme type was CTX-M-15 76% (63/83), followed by 
CTX-M-14 14% (11/83). From this study, a novel CTX-M ESBL was identified from a K. 
pneumoniae isolate (laboratory number ARS06/441). This was designated CTX-M-68 by the 
Lahey Clinic (H. M. Heffernan et al., 2009). A subsequent study using non-duplicate isolates 
of ESBL E. coli  at the Auckland hospital laboratory found that 55% (59/108) were CTX-M-
15, followed by 27% (29/102) CTX-M-14 (Freeman et al., 2012). In addition, a prospective 
unmatched case control study conducted in 2017 in Auckland and Northland regions on human 
urine samples from people that had UTI and kept at least 1 pet, found a prevalence of 68% 
(90/132) of ESBL/AmpC producing E. coli with blaCTX-M-15 and blaCMY-2 as the predominant 
gene types (Toombs-Ruane et al., 2019). Co-resistance with other classes of antibiotics was 
observed in all these studies. 
A cross-sectional  study conducted by Karkaba et al. (2017) in companion animals reported a 
prevalence of 60% (36/60) for carriage  ESBL/AmpC producing E. coli in cats and dogs. This 
study reported blaCTX-M-14 as the most prevalent gene type (4/10) and co-resistance with other 
classes of antibiotics was observed (Karkaba et al., 2017). Another study conducted  10 years 
ago (2009-2010), a surveillance study of various food products (pig, poultry and calf) across 
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New Zealand, showed that none of the 1000 isolates recovered were ESBL/AmpC positive (H. 
Heffernan et al., 2011). 
1.7 Detection of AmpC/ESBL producing E. coli 
Accurate identification of ESBL/AmpC producing pathogens is crucial in the selection of 
appropriate antibiotic therapy. It also helps in adopting proper control measures to reduce cross 
transmission of bacteria between patients, and for surveillance purposes (Pfaller & Segreti, 
2006). The standardised methodologies for phenotypic detection of AmpC/ESBL producing E. 
coli are available from both Clinical and Laboratories Standards Institute (CLSI) (CLSI, 2017) 
and European Committee on Antimicrobial Susceptibility Testing (EUCAST) (EUCAST, 
2020). Both CLSI and EUCAST recommend a 2-step method, first by screening, followed by 
a confirmatory test. For ESBL, reduced susceptibility to at least two of the indicator 3rd 
generation cephalosporins (cefpodoxime, cefotaxime, ceftriaxone or ceftazidime) is 
recommended for screening,  followed by a double-disk diffusion synergy test of the indicator 
cephalosporins (cefotaxime, ceftazidime) and clavulanic acid (Bajaj et al., 2016; Stürenburg & 
Mack, 2003). Unlike ESBLs, there are no recommended guidelines for the detection of AmpC 
producing E. coli. Nevertheless, a reduced susceptibility to cefoxitin may be used for screening, 
followed by a confirmatory test of cefoxitin–cloxacillin or boronic acid combination disk 
method (Bajaj et al., 2016).  
It is important to distinguish ESBL-producing E. coli from AmpC-producing E. coli, as failure 
to do so may result in serious public health impacts, ranging from treatment failure to 
emergence of new resistant bacteria.  
Despite the availability of various phenotypic methods, molecular biology techniques such as 
PCR and whole genome sequence analysis serve as gold standards for detection, identification 
and differentiation of different genes encoding for ESBL/AmpC, even though they are less 
applied in many clinical laboratories because of their cost and lack of expertise (Bradford, 
2001). However, the use of whole genome sequencing is becoming more common in co-
ordinated studies investigating ESBL-E from a national prevalence perspective (Heffernan et 
al., 2018). 
Beside the molecular techniques mentioned above, another method Matrix Assisted Laser 
Desorption Ionization Time of Flight Mass Spectrometry (MALDI-TOF MS) has been utilised 
in the detection and identification of various pathogens including the ESBL/AmpC producing 
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E. coli (Angeletti, 2017; Dekker & Branda, 2011). This method is more rapid than the 
traditional lengthy phenotypic identification method. MALDI-TOF MS has a higher 
sensitivity, making it a preferred method to use in hospital-based and other research 
laboratories. MALDI-TOF MS rapid and accurate diagnosis leads to fast administration of 
effective antimicrobials and this contributes to a reduced mortality and hospitalization time of 
patients and consequently has a significant impact on cost reduction and public health 
(Angeletti, 2017). 
1.8 Role of dairy farms in dissemination of resistant bacteria 
The use of antimicrobials in livestock has come under critical review, due to the association of 
“routine” antimicrobial use in livestock with the development of antimicrobial resistance. As a 
result, there has been a global call to develop guidelines that safeguard the use of antibiotics. 
These include restricting their usage, develop proper legislative action and vigorous research 
to produce other antibiotics (WHO, 2015). In line with this call, the New Zealand Veterinary 
Association (NZVA) has stated that by 2030, antibiotics will be reserved for treatment of 
diseases only, rather than for animal health maintenance and welfare (NZVA, 2018). 
Guidelines for AMU vary in many countries. While some countries such as USA and China 
allow the use of antibiotics as growth promoters in addition to therapeutic treatment, this is 
prohibited in New Zealand and some European countries where antibiotics are used solely to 
treat animal diseases and not as growth promoters (FDA, 2010; Maron et al., 2013). AMU also 
differs between conventional and organic dairy farms. Unlike conventional dairy farms, 
organic dairy farms do not permit the use of antibiotics, unless the animal is sick, in which case 
it is isolated from the rest of the herd to be treated. In the USA it will not be returned to the 
herd, while in European countries, it will be returned but there is longer milk withholding 
period (Maron et al., 2013). In New Zealand, on the other hand, the use of antibiotics in organic 
farming is banned (with some exceptions) in order to meet the export market requirements 
(AsureQuality, 2018). 
Generally, low antibiotic use is reported in cattle, compared to other food animals such as swine 
or poultry (Marshall & Levy, 2011). In dairy cattle, antibiotics are used for various reasons. 
These include; treating infections related to calving e.g. endometritis, metritis, retained foetal 
membranes, mastitis and infections not related to calving, such as Dry Cow Therapy (DCT). A 
study carried out in New Zealand by Compton et al., (2014) found that 86% of antibiotics were 
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used mainly for DCT and treatment for mastitis. It should be noted that antibiotic use in animals 
is lower in New Zealand compared to other countries according to a study conducted by 
Hillerton et al. (2017). In this study, New Zealand was third lowest in the use of antibiotics in 
food animals. This is due to the extensive pasture-based system practiced on most dairy farms 
in the country that could mean low risk of exposure to infections from the environment and 
thus healthier animals (Hillerton et al., 2017). To show more prudent AMU, the NZVA has 
provided guidelines on the use of antibiotics in dairy cattle and have grouped the antibiotics 
according to the criteria set by WHO and OIE (WHO, 2019). A traffic light system is used to 
rank classes of the antimicrobials. Those that should be used as first line therapy have been 
grouped as green. Yellow are restricted antibiotics that should only be used as second line 
therapy and the final group has red colour which are considered critical important and should 
only be used when there is a need to do so under prescription from a veterinarian. 3rd and 4th 
generation cephalosporins, Macrolides and Fluoroquinolones belong to the red colour group 
(NZVA, 2018) 
Different classes of antibiotics are used in dairy livestock for various clinical reasons, some of 
which have been highlighted in the previous paragraph. Of concern are the 3rd and 4th 
generation cephalosporins which have been associated with the emergence of ESBL-E and 
AmpC producing pathogens. A cross-sectional study conducted in the Netherland found that 
the positive ESBL/AmpC status of the dairy herds was linked to the use of 3rd and 4th generation 
cephalosporins (Gonggrijp et al., 2016). Similarly, Snow et al. (2012) reported a higher 
likelihood of positive ESBL/AmpC status in dairy herds that used 3rd and 4th generation 
cephalosporins. Furthermore,  Randall et al. (2014) observed greater shedding of CTX-M 
positive E. coli in calves that were fed waste milk containing cefquinome a fourth generation 
cephalosporin.  
The prevalence of ESBL/AmpC producing E. coli in dairy cattle (milking herd, heifers, calves) 
is unknown in New Zealand. To date, only one published study has investigated AMR 
surveillance of various food products from pig, poultry and calves across New Zealand and 
none of the 999 E. coli isolates were ESBL/AmpC positive (H. Heffernan et al., 2011). 
However, unpublished data of a cross-sectional study on lower North Island dairy farms found 
6% (1/15) farms were positive for ESBL-producing E. coli (Aplin et al., 2018; unpublished 
data). Another unpublished study on calves fed either waste or non-waste milk from 12 
Waikato dairy farms found that none of the E. coli isolates (n = 191) were ESBL/AmpC 
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producing (Kelly et al, 2016, unpublished data). Globally, numerous studies have reported the 
prevalence and incidence of ESBL/AmpC-producing E. coli and the associated enzyme type in 
dairy cattle (Table 2). However, the results varied widely depending on the sample size, sample 






















Table 2. Prevalence of ESBL/AmpC producing E. coli in dairy farms 
Sample type  
 Country Detection method Prevalence ESBL/AmpC gene 
type 
Reference 









4 E. coli isolates positive for 
Extended spectrum cephalosporins 
(ESC) selected from a previous 





Awosile et al. (2020) 







40% (8/20) of the farms were 







Hordijk et al. (2019) 
15 
 
Faeces from dairy 
cattle and veal calves 
 
Netherlands Culture-based:  
Selective media 
(cefotaxime) after 




ESC E. coli isolates from veal calves 
increased from 17.9% (54/301) in 
2014, to 37% (114/302) in 2017 
while in  
dairy cattle prevalence increased 
from 8.7% (26/300) in 2014, to 





Were common in 
both Veal calves and 
cattle 
(Ceccarelli et al., 2019) 




11.1% (20/180) of E. coli isolates 
were ESBL/AmpC producing 
blaCTX-M 
blaCMY 
Terentjeva et al. (2019) 
Faeces from calves, 
young stock and 
dairy cows 
Netherlands Culture-based:  
Selective media 
(cefotaxime) 
48.6% (89/183) of calves, 15.3% 
(29/183) young stock and 23% 
(42/183 cows harboured 










Faeces from dairy 
cows  




43.6% (284/651) of E. coli isolates 





Zheng et al. (2019) 
Environmental 







79.2% (42/53) of the farms were 
positive for cefotaxime-resistant E. 
coli and 5.4% (224/4145) of the 
isolates were cefotaxime-resistant  
blaCTX-M   
      
Schubert et al. (2019) 
 
Bulk Tank milk  Turkey Culture-based:  
Selective media 
(ChromID ESBL) 
22.6% (14/62) of the isolates were 
ESBL producing E. coli 
blaCTX-M-15  
blaCTX-M-55 
Kürekci et al. (2019) 
Rectal faecal swabs Canada Culture-based: 81.2% (396/488) of the E. coli 
isolated over the study period were 
blaCMY-2 
blaCTX-M-2 







positive for ESC.  52% (205/488) of 
the calves were positive at both 









13% (12/90) of the herds were 
ESBL/AmpC positive 
Not determined  Santman-Berends et al. 
(2017) 
Feaces from stable 
floor, dust samples 
and boot swabs from 
feed alley of the 
dairy farms 
 Germany Culture-based: 
Enriched with 
(LB) broth, then 
selective media 
(cefotaxime). 
48% (156/323) of the combined 
samples were ESBL/AmpC 
positive. 
Not determined 
            
Hille et al. (2017) 




 Turkey  Culture based: 
Selective media 
(cefotaxime) 
5.8% (10/172) of the E. coli isolates 
were ESBL/AmpC producing. 
blaCTX-M-15  
blaCTX-M-1  
blaCTX-M-3   
blaCMY-2  









3.1% (4/129) of the milk samples 
harbored ESBL/AmpC producing E. 
coli  
 blaCTX-M-15 
blaCTX-M- 155  
 








41% (41/100) of the herds were 








encoded ampC gene  
Gonggrijp et al. (2016) 
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75.6% (62/82) E. coli isolates were 
ESBL/AmpC producing  
blaCTX-M-1  
 
Odenthal et al. (2016) 
Rectal swabs from 
dairy cattle 
Egypt Culture based:  
Enriched with BPW 
then slective agar 
46.6% (98/210) E. coli isolates were 




Braun et al. (2016) 
Faeces from veal 
calves 
 France Culture-based: 
selective agar 
(ChromID ESBL) 
29.4% (144/489) of E. coli isolates 




Haenni et al. (2014b) 





18-26% of the farms were positive 
for ESBL/AmpC at the time of 
calves arrival, this decreased during 




Hordijk et al. (2013a) 
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Pooled fecal samples 




In 1998 4% (4/49) of the E. coli 
isolates were ESBL/AmpC 
producing while 39% (71/182) was 





              
Hordijk et al. (2013c) 





66% (66/100) of the herds harbored 
ESBL/AmpC producing E. coli and 
within- herd prevalence ranging 




Hordijk et al. (2013b) 
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Besides AMU, other farm management practices such as feed, housing system and hygiene 
have been associated with  AMR on dairy farms (Gonggrijp et al., 2016; Snow et al., 2012). A 
study by Gonggrijp et al. (2016) found floor scrappers which are used for cleaning pens, was 
associated with positive ESBL/AmpC herd status.  Lacy-Hulbert et al. (2002) found higher 
incidences of AMR in cows fed total mixed ration feed (silage and concentrates) than those fed 
all- pasture diet.  
Potential pathways for transmission of ESBL/AmpC producing E. coli from the dairy farm 
environments to humans have been hypothesised (Collis et al., 2019; Horigan et al., 2016). 
These include: 1) direct contact with the infected animal or contaminated faeces, 2) through 
food chains such as drinking raw milk or undercooked meat or 3) through contaminated water 
(Dahms et al., 2015; Valentin et al., 2014; Van Elsas et al., 2011) (Figure 2). However, various 
studies have reported low to no evidence of transmission between livestock and  humans, and 
interventions to avoid transmission are recommended (Alzayn et al., 2020; Findlay et al., 2020; 







Figure 2. Potential transmission pathways of the ESBL/AmpC producing E. coli. Orange 
colour represent the main drivers of AMR, green colour represents the various transmission 
pathways of ESBL/AmpC producing E. coli while arrow direction shows the relationship. 




1.9 Role of waste milk use in dairy calves in disseminating ESBL/AmpC producing E. 
coli  
Waste milk is milk that is unfit for human consumption. It includes milk from cows that have 
been treated with antibiotics, other types of drugs or with increased somatic cell counts (over 
150,000 cells/ml) before withholding period is over (EFSA, 2017). Some studies have reported 
the use of waste milk as feed in dairy farms, for different groups of calves (raised for veal, 
replacement stock or beef) as an alternative to milk replacers or non-waste milk (Duse et al., 
2013; Tempini et al., 2018). However, this is not recommended, as waste milk has been linked 
to the development of ARB (Foutz et al., 2018). In addition to that, it has been hypothesised 
that milk containing antibiotic residues is unpalatable to calves, and this might lead to reduced 
intake, resulting in poor calf growth, poor performance and less weight gain, however this 
hypothesis has not been proven (Aust et al., 2013; Brunton et al., 2014; Thames et al., 2012). 
The development of ESBL/AmpC-producing E. coli in calves, due to feeding with waste milk 
is of concern. A study conducted in England observed an increased number of CTX-M-
producing E. coli isolates (25/45) from calves that were fed waste milk containing cefquinome, 
a 4th generation cephalosporin, compared to the control group (18/45) even though statistically 
there was no significant difference (Brunton et al., 2014). Subsequent studies conducted in 
USA and Germany  reported isolation of ceftiofur  and cefotaxime resistant E. coli in calves 
that were fed waste milk containing 3rd generation cephalosporins (Aust et al., 2013; Berge et 
al., 2006).  
To the authors’ knowledge, no study has investigated the prevalence of ESBL/AmpC 
producing E. coli in waste milk fed calves in New Zealand, although both NZVA and NZ Dairy 
Industry does not recommend the use of waste milk as feed in calves 
https://www.dairynz.co.nz/news/waste-milk-is-it-calf-feed/. However, studies undertaken 
overseas have reported prevalence ranging from 18 to 94% (Table 3) with results varying 





Table 3. Prevalence of ESBL/AmpC producing E. coli in waste milk fed calves 
Sample type Country Detection 
method 
Prevalence ESBL/AmpC gene 
type 






94% (87/126) of the E. 
coli isolates were 
positive for AmpC and 
none for ESBL. 
blaCMY-2 
 
A (3/10), B1 (1/10), 
B2 (1/10), C (3/10), 
D (2/10) 
                   
Manga et al. 
(2019) 




Not determined   Not determined  Not determined  Tetens et al. 
(2019) 
 






42.2% (75/178) of E. 
coli isolates were 
resistant to ceftiofur in 
calves fed waste milk 
while 21.5% (27/178) 
of E. coli isolates 








were from calves fed 
milk replacer.   






50% (32-64%) and 
77% (60-90%) of E. 
coli isolates were 
positive for CTX-M in 
the control and 
treatment group 
respectively. 
blaCTX-M  Not determined  Brunton et al. 
(2014) 
Faeces  UK Culture based: 
Enrichment with 
BPW then 
selective media  
75% (12/16) of CTX-
M producing E. coli  
 blaCTX-M  Not determined  Randall et al. 
(2014) 
Faeces Germany Culture based: 
Selective media 
18% (9/50) of E. coli 
isolates were resistant 
to cefotaxime in waste 
milk fed calves, 20.8% 
Not determined  Not determined       Aust et al. (2013) 
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(10/40) from calves 
fed pasteurized waste 
milk and 4.8% (2/42) 






1.10 Relevance of this study 
Every year more than two million bobby calves are slaughtered in New Zealand 
https://www.mpi.govt.nz/. Most bobby veal meat is exported to Asian countries (mainly 
Thailand, China and Hong Kong) for human consumption and the remainder is used to make 
pet food. Therefore, presence of ESBL/AmpC E. coli in bobby calves poses a public health 
concern if good hygiene practices are not followed at slaughter and during veal processing 
which may lead to carcass contamination and this may subsequently be transferred into food 
chain and the environment. This problem can be exacerbated when food safety practices such 
as proper cooking and proper food storage are not observed. 
A lack of data on the prevalence of ESBL/AmpC producing E. coli in dairy calves fed with 
waste milk, prompted this observational study to be conducted by analysing culture 
enrichments from a previous national cross-sectional study that estimated the prevalence of 
Shiga toxin-producing E. coli in dairy calves (Browne, 2018) . We hypothesize that 
ESBL/AmpC producing E. coli will be present in the faeces of waste-milk fed calves. Using 
both culture-based isolation methods and whole genome sequencing, this study aims to; 1) 
determine the prevalence of ESBL and AmpC producing E. coli isolated from recto-anal 
mucosal swabs from waste milk fed dairy calves and 2) phenotypically and genotypically 












2 Materials and methods 
This study used samples and information collected by Springer Browne for his PhD study 
(Browne, 2018). Springer’s study was approved by The Animal Ethics Committee of Massey 
University, Palmerston North, New Zealand on 17thApril 2014, under protocol number 14/29. 
2.1 Sample Collection 
Recto-anal mucosal swab samples (RAMS) were collected using Amies transport swabs 
(Copan Diagnostics Inc., Brescia, Italy), by Springer Browne for his PhD study from calves 2 
to 21 days old. Sampling was carried out during the spring calving season, 28th July to 24th 
September 2014 across six regions (Northland, Waikato, Taranaki, Manawatu-Wellington, 
Canterbury and Southland) in New Zealand. All RAMS collected were shipped on ice 
overnight to the mEpiLab, Massey University, Palmerston North, and enriched with modified 
Tryptone Soy Broth (mTSB, Oxoid Limited, Hampshire, United Kingdom) at 42°C for 15-21 
hours in preparation for further processing. All samples were later suspended in glycerol (4:1 
ratio)  and stored in a -80°C freezer for future use (Browne, 2018). This present study only 
used samples collected from the Canterbury region from waste milk user farms (Appendix A). 
Forty samples from four farms that used waste milk in the Canterbury region were randomly 
selected, each contributing 10 calves aged 2 to 9 days old. The RAMS were from mixed-sex 
calves meant either for bobby (veal meat), heifer replacement, or for beef (Appendix B). 
2.2 Screening for Escherichia coli 
MacConkey agar supplemented with antibiotics was prepared for screening of ESBL/AmpC 
producing E. coli.  Cefotaxime and ceftazidime (Sigma-Aldrich New Zealand Co., Auckland, 
NZ) antibiotics were previously prepared by dissolving in Milli-Q water to a stock 
concentration of 10mg/ml and filter sterilized using a 0.22µm filter syringe (Merck MF-
Millipore Membrane filter). The prepared antibiotic stocks were stored at -80°C. Each working 
stock of cefotaxime and ceftazidime was added into a different bottle of the molten MacConkey 
agar (Difco™, BD) to make a final concentration of 1mg/ml and poured into petri dishes. These 
were dried and stored in the cold room. The enriched frozen RAMS were then removed from 
the freezer and streaked on to the four different types of media: Plain MacConkey (Fort Richard 
Laboratories, Auckland, NZ), MacConkey with cefotaxime (MAC + CTX), MacConkey with 






were incubated at 35°C for 16 to 24 hours. After incubation, two single lactose positive colonies 
that had different morphologies (dark pink colonies) from each MacConkey (with and without 
antibiotics) plate were chosen randomly, as well as two purple, pink or blue coloured colonies 
from the ESBL CHROMagar. Each colony was purified on Columbia Horse Blood agar (Fort 
Richard, Auckland, NZ) and incubated overnight. Finally, presumptive E. coli isolates were 
collected with sterile cotton swabs and added into 15% glycerol broth for cryopreserving at -
80°C.   
Presumptive E. coli isolates were subjected to confirmation using matrix-assisted laser 
desorption ionization time of flight mass spectrometry (MALDI-TOF MS; MALDI Biotyper® 
System, Bruker Daltonics Inc, Billerica, MA, USA). Using a sterilised toothpick, a small 
amount from a single colony was picked and spotted on to the biotyper target plate and overlaid 
with 70% formic acid. The spots were air-dried and overlaid with 1µl of alpha-Cyano-4-
hydroxycinnamic acid (HCCA) matrix (Bruker Daltonics Inc, Billerica, MA, USA). The 
samples were analysed in duplicate using the MALDI Biotyper and MBT Compass (v4.4.100) 
software package (Bruker Daltonics Inc, Billerica, MA, USA). The confirmed E. coli and 
Klebsiella pneumoniae isolates were further screened for ESBL production and multi-drug 
resistance using an antibiotic susceptibility test (AST).   
2.3 Screening for ESBL/AmpC producing E. coli 
The Mastdiscs® AST (Mast Group Ltd., Merseyside, UK) antibiotic discs were used for the 
screening of ESBL and/or AmpC producing isolates. Following guidelines from EUCAST, 
cefotaxime (CTX) 30µg, cefpodoxime (CPD) 30µg were used for screening of ESBL 
production (EUCAST, 2020). Cefoxitin (FOX) 30µg was used for screening of potential AmpC 
producers (Bajaj et al., 2016). To test for multidrug resistance; streptomycin (STR) 10µg, 
tetracycline (TET) 30µg and ciprofloxacin (CIP) 5µg antibiotic discs were used along with the 
ESBL/AmpC screening discs (Figure 3). The ASTs were performed according to guidelines 
from both CLSI and EUCAST (CLSI, 2017; EUCAST, 2020). E. coli reference strain ATCC 
25922 (NZRM 916) was used as a control strain.  Purified isolates were streaked on Columbia 
Horse Blood Agar (Fort Richard, Auckland, NZ) and incubated at 35°C for 16–24 hours. Using 
a sterile cotton swab, colonies were transferred to sterile saline solutions to prepare the 
suspension with an optical density of 0.5 McFarland. The suspensions were spread onto 
Mueller-Hinton agar (Fort Richard, Auckland, NZ) in three directions using a sterile cotton 






Disc master Dispenser). After incubation at 35°C for 20 hours, the inhibition zones were 
measured using a caliper. The antibiotic discs used in this study and their breakpoints are shown 
in Table 4.  The isolates which were resistant to either cefotaxime, cefpodoxime or cefoxitin 
were considered as potential ESBL and/or AmpC producing E. coli.    



















10 21 21 EUCAST 
Cefoxitin 
(FOX) 
Cephamycin 30 19 19 EUCAST 
Ciprofloxacin 
(CIP) 
Fluoroquinolone 5 22 22 EUCAST 
Streptomycin 
(STR) 
Aminoglycoside 10 15 11 CLSI 
Tetracycline 
(TET) 
Tetracycline 30 11 15 CLSI 








2.4 Epidemiological cut-Off values (ECOFFs) 
Epidemiological cut-off values (ECOFFs) of the E. coli population were defined using the 
normalised resistance interpretation (NRI) method, as described by Kronvall and Smith (2016). 
Disc diffusion zone diameter results of the 6 antibiotics (CTX, CPD, FOX, STR, TET,CIP) 
were used in an already developed spreadsheet file 
http://www.bioscand.se/nri/Automatic_NRI-zone_2019.xlsm. Normal distribution curves for 
each antibiotic were generated after entering the number of isolates under the given zone 
diameters. The means and standard deviations generated from these normal distribution curves 
were used to produce the breakpoints (ECOFFs), categorising the strains as wild-type (fully 
susceptible) and non-wildtype (reduced susceptibility). The ECOFFs were compared with the 
EUCAST/CLSI breakpoints. 
2.5 ESBL and AmpC Confirmation  
Potential ESBL and/or AmpC producing isolates were confirmed by the disc diffusion method 
using Mastdisc™ Combi ESBL (D64C and D62C)and AmpC (D69C) detection sets (Mast 
Group Ltd., Merseyside, UK) according to EUCAST guidelines (EUCAST, 2020) . For the 
detection of ESBL production, zone diameters were determined for cefotaxime; 30μg (disc A), 
ceftazidime; 30μg (disc B), cefotaxime; 30μg + clavulanic acid; 10μg (disc C) and ceftazidime; 
30μg + clavulanic acid; 10μg (disc D). Zone size differences between either disc A and C, or 
disc B and D, larger than 5mm were considered ESBL positive. For the detection of AmpC 
producing E. coli, zone diameters were determined for cefpodoxime; 10μg + AmpC inducer 
(disc A), cefpodoxime; 10μg + AmpC inducer + ESBL inhibitor (disc B), and cefpodoxime; 
10μg + AmpC inducer + ESBL inhibitor + AmpC inhibitor (disc C). The zone size of disc C 
was then compared with those of both discs A and B. If both zone size differences were larger 
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1MacConkey agar  
2MacConkey agar with antibiotics cefotaxime (CTX) and ceftazidime (CAZ), 1mg/ml 
concentration  
3Antibiotic sensitivity disc; cefotaxime (CTX), cefpodoxime (CPD), cefoxitin (FOX), 
ciprofloxacin (CIP), tetracycline (TET) and streptomycin (STR) 
Figure 3. Flow process of detection of ESBL/AmpC producing E. coli 
2.6 AmpC Genotypic Confirmation 
Confirmed AmpC producing isolates were further analysed by PCR to determine if they were 
chromosomal or plasmid mediated AmpC. Crude DNA extractions were prepared using the 
heat lysis method. Three or four colonies of confirmed AmpC producing E. coli isolates were 
collected from the Columbia Horse Blood Agar plates (Fort Richard, Auckland, NZ), using 
disposable loops and suspended in 1ml of nuclease-free water in an Eppendorf tube. The 
Eppendorf tubes were incubated at 102°C with 1,200 rpm shaking speed for ten min using a 
Provocell™ Microplate Shaker/Incubator (ESCO Micro Pte Ltd, Singapore). The Eppendorfs 
were then cooled down for 10 min at room temperature and centrifuged at 12,000 rpm for 3 
min in a microcentrifuge (Sigma 1-14, Sigma Laborzentrifugen GmbH, Germany). The 
supernatants were transferred into new Eppendorf tubes to be used for PCR. Isolates were 
analysed for the presence of genes encoding the plasmid-mediated AmpC enzymes (MOX, 
CIT, DHA, ACC, FOX), and the promoter region of the ampC chromosomal gene as described 
by Caroff et al. (1999) and Pérez-Pérez and Hanson (2002). 
The AmpC multiplex PCR reaction mix was made using 4µl DNA polymerase mastermix (Hot 
fire Pol®), 1µl of each 10µM forward and reverse primer and 5µl PCR-grade water. Each PCR 
reaction was prepared in a total volume of 20µl containing 19µl of the PCR mix and 1µl of the 
template and was performed in a SensoQuest PCR machine. The multiplex PCR program 
consisted of 3 min at 95°C, followed by 25 cycles of 95°C for 30 s, 64°C for 30 s and 72°C for 
60 s, followed by one final cycle of 72°C for 7 min. The ampC promoter region PCR reaction 
mix was made of 4µl DNA polymerase mastermix (Hot fire Pol®), 1µl of each 10µM forward 
and reverse primer and 13µl PCR-grade water. Each PCR reaction was prepared in a total 
volume of 20 µl containing 19 µl of the PCR mix and 1 µl of the template. and performed in a 






from the annealing temperature which was 57°C in a SensoQuest PCR machine. The list of 
primers used in this study is shown in Table 5. 
The PCR amplicons were then analysed using gel electrophoresis by running 5 ul of each PCR 
product on a 2% agarose gel containing 10µl nucleic acid gel stain (Gelred®, Biotium, Fremont, 
California, USA) for 90 min at 80V. The gel was visualized using a UV trans-illumination 











Table 5. Primers used for AmpC detection in E. coli isolates 
Enzyme  
 


























4, CMY-2 to 









































 Caroff et al. 
(1999) 






2.7 Sequencing of the ampC promoter region 
Confirmed chromosomal AmpC producing isolates were further sequenced to determine 
mutations in the promoter and attenuator regions. The promoter PCR amplicons were purified 
using the QIAquick® PCR purification kit (Qiagen, Hilden, Germany) as per the 
manufacturers’ instructions. The purified PCR product was eluted in 50ul of water. The quality 
of the purified PCR product was checked with a Nanodrop® (ThermoFisher Scientific, 
Massachusetts, United States) spectrophotometer.  
The purified PCR product was prepared for sequencing by adding 17µl of PCR-grade water, 
1µl of forward AmpC promoter primer (AmpC171) and 2 µl of the purified PCR sample to 
make a total volume of 20µl. This was repeated with the reverse primer (AmpC2120). These 
were sent to Massey Genome Service (Massey University, Palmerston North, New Zealand) 
for Sanger sequencing. Sequencing results were analysed using Geneious software v10.2.6 
(Biomatters, Ltd. Auckland, New Zealand), and compared with the reference strain E. coli 
ATCC 25922 (Accession number CP009072) as described by Tracz et al. (2007). 
2.8 Phylogrouping 
Confirmed resistant E. coli isolates were phylotyped by quadraplex PCR as described by 
(Clermont et al., 2013). DNA extraction was carried out using the heat lysis method. The 
quadraplex PCR reaction mix was made using 10 µl of DNA polymerase mastermix (Kapa 
Hifi, Kapa Biosystems, Cape Town, South Africa), 0.6 µl of each of the primers and 4.2µl of 
PCR-grade water. Each PCR reaction was prepared in a total volume of 20µl containing 19µl 
of the PCR mix and 1µl of the template and performed in a SensoQuest PCR machine. The 
quadraplex PCR programme consisted of four minutes of initial denaturation at 94°C, followed 
by 30 cycles of denaturation at 98°C for 20 s, 20 s of annealing at 61°C, and 5 min of extension 
at 72°C. The PCR amplicons were then analysed with gel electrophoresis by running 5 µl of 
each PCR product on a 2% agarose gel containing 10µl nucleic acid gel stain (Gelred®, 
Biotium, Fremont, California, USA) for 2 hours at 80V. The gel was visualized using a UV 









Table 6. primers used in phylogrouping of E. coli isolates (Clermont et al., 2013) 
Primer 
name  




arpA AceK.f 5′-AACGCTATTCGCCAGCTTGC-3′  
arpA 
 
400 ArpA1.r 5′-TCTCCCCATACCGTACGCTA-3′ 
chuA chuA.1b 5′-ATGGTACCGGACGAACCAAC-3′  
chuA 
 
288 chuA.2  5′-TGCCGCCAGTACCAAAGACA-3′ 
yjaA yjaA.1b 5′-CAAACGTGAAGTGTCAGGAG-3′  
yjaA 
 
211 yjaA.2b 5′-AATGCGTTCCTCAACCTGTG-3′ 
TspE4C2 TspE4C2.1b 5′-CACTATTCGTAAGGTCATCC-3′  
TspE4C2 
 
152 TspE4C2.2b 5′-AGTTTATCGCTGCGGGTCGC-3′ 
 
2.9 Whole genome sequencing, assembly and analysis  
12 resistant (tetracycline, streptomycin, cefpodoxime, cefoxitin) E. coli isolates across the 4 
farms were selected for whole genome sequencing. Genomic DNA was extracted using the 
QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) as per the manufacturers’ instructions. The 
DNA was eluted in 50µl of sterile PCR-grade water. 
The DNA quantity and quality were determined using fluorometry, the dsDNA HS Assay 
(Qubit 2.0, Invitrogen, Carlsbad CA, USA), spectrophotometry using the Nanodrop® 
(ThermoFisher Scientific, Massachusetts, USA) as per the manufacturers’ instructions. The 
integrity of the DNA was checked using gel electrophoresis. 5µl of each DNA extraction was 
loaded onto a 0.8% agarose gel (Bioline®), stained with a nucleic acid gel stain (Gelred®, 







The genomic DNA was diluted in PCR-grade water to a total volume of 15µl. The library 
preparations and next-generation sequencing were performed by Massey Genome Sequence 
(Massey University, Palmerston North, New Zealand). The Illumina Nextera™ XT library 
preparation kit (San Diego, California, U.S.A) was used to prepare the libraries as per the 
manufacturers’ instructions and sequencing was performed on an Illumina MiSeq™ (San 
Diego, California , U.S.A). 
Raw sequences were processed and assembled using the Nullarbor pipeline (v. 2.0.20181010) 
by using the raw pair-ended FASTQ read file as input and using the reference accession 
CP014316 (Seemann et al., 2018). A core single nucleotide polymorphism (SNP) analysis was 
carried out using the internal reference CE0015a and a neighbour-joining tree generated using 
SplitsTree (v.4.16.1) (Huson & Bryant, 2006) which was annotated using the Interactive Tree 
of Life (iTOL) software (Letunic & Bork, 2019) and Inkscape open source software 
(v.1.0.1)(https://inkscape.org). 
2.10 Statistical Analysis  
The package ggplot from R studio software (v.3.6.3) was used to visualise the frequency of 








3 Results  
3.1 Prevalence of E. coli from the four dairy farms 
A total of 40 rectoanal mucosal swab enrichment samples from waste milk-fed dairy calves 
from four dairy farms were screened for E. coli. A total of 109 isolates recovered from 39 calf 
samples (no isolates were recovered from calf sample VC1128/CE0001 from farm VCF77), of 
which 78/109 were isolated from plain MacConkey, 17/109 from MacConkey with ceftazidime 
(MacConkey + CAZ), 14/109 from MacConkey with cefotaxime (MacConkey +CTX) and 
none from CHROMagar ESBL (Appendix C). From the 109 isolates recovered, 95.4% 
(104/109) were Escherichia coli and 4.6% (5/109) were Klebsiella pneumoniae. The number 
of suspected ESBL/AmpC positive isolates from MacConkey with antibiotics (ceftazidime or 
cefotaxime) were almost similar across farms VCF77, 79 and 89 (Figure 4). No isolates were 
recovered from MacConkey with antibiotics from farm VCF80 as indicated in Figure 4. 
Further details on the recovered isolates are in Appendix C. 
 
Figure 4. Number of E. coli isolates recovered from different medium from each of the four 
farms. MacConkey plain: MacConkey without antibiotic, MacConkey + CTX: MacConkey 







3.2 Antimicrobial resistant profiles 
The 109 recovered isolates were tested for antimicrobial resistance using six different 
antibiotics. The antibiotic susceptibility test results together with their zone diameters are 
reported in Appendix C and summarised in Table 7. Among the 104 E. coli isolates, 45% 
(47/104) were sensitive to all the six antibiotics used and 55% (57/104) showed resistance to 
at least one of the antibiotics. More of the E. coli isolates, 39% (41/104), were resistant to 
tetracycline than any other antibiotic, whilst 18% (19/104) showed resistance to streptomycin. 
Co-resistance to tetracycline and streptomycin was observed in 17% (18/104) of the E. coli 
isolates. 30% (31/104) of the isolates showed resistance to cefpodoxime and cefoxitin. These 
were suspected of being ESBL/AmpC producing and were subjected to further ESBL/AmpC 
confirmation test. No isolates showed resistance to three or more classes of antibiotics; hence 
no multidrug resistance was observed. In addition, none of the isolates showed resistance to 
cefotaxime and ciprofloxacin (Table 7) and none of the K. pneumoniae isolates showed 
resistance to any of the antibiotics.  
Overall, 58% (23/40) (95% CI 41% - 73%) of the calves harboured antibiotic resistant E. coli.   
Of these 23 calves 18 harboured E. coli isolates that were resistant to tetracycline, 13 harboured 
E. coli isolates that showed resistance to streptomycin and 10 harboured E. coli isolates that 
showed resistance to cefpodoxime and cefoxitin. There were 12 calves that harboured E. coli 
isolates that were co-resistant to tetracycline and streptomycin, and none of the calves 
harboured isolates that were resistant to cefotaxime or ciprofloxacin (Figure 7).  
Table 7. Number and percentage of E. coli isolates showing resistance to the six antibiotics 
based on the diffusion test 
Farm ID Total 
number 
of E. coli 
isolates 
Number of resistant E. coli isolates (%) 
CTX1 CPD1 FOX1 CIP2 TET3 STR4 R2 
VCF77 27 0 12 12 0 5 5 5 






VCF80 20  0 0 0 0 11 10 10 
VCF89 26 0 8 8 0 16 4 11 
Total  104 0(0) 31(30) 31(30) 0(0) 41(39) 19(18) 34(33) 
CTX1: cefotaxime; CPD1: cefpodoxime; FOX 1: cefoxitin (cephalosporins)  
CIP2: ciprofloxacin (fluoroquinolones)  
TET3: tetracycline (tetracyclines)  
STR4: streptomycin (aminoglycosides) 
R2: resistant to two classes of antibiotics 
3.3 Normalised resistance interpretation (NRI) 
Epidemiological Cut-Off values (ECOFFs) of the E. coli population were defined by using the 
normalised resistance interpretation (NRI) method. Disc diffusion zone diameter results of the 
6 antibiotics (CTX, CPD, FOX, STR, TET, CIP) from Appendix 1 were used. A normal 
distribution curve for each antibiotic (Figure 5) was generated by entering the number of 
isolates according to their zone diameters. The ECOFFs generated were used to categorise the 
strains as wild-type (fully susceptible) and non-wildtype (reduced susceptibility). The NRI 
ECOFFs were compared with the EUCAST/CLSI clinical breakpoints (Table 8).  
The highest percent of 41% (43/104) of non-wild type E. coli strains, were observed under 
tetracycline, followed by cefotaxime which had 36% (37/104) isolates displaying non-wild 
type. Noticeably, two populations of isolates were observed under cefotaxime (Figure 5a). 
Two separate curves were used to represent this, a and b (Figure 6) with a single isolate and 
three isolates displaying non-wild type in population a and b respectively. No isolate displayed 








Table 8. Antibiotics used in this study with NRI-ECOFFs values compared with the 









5 20 31 
Cefpodoxime 
(CPD) 
10 21 24 
Cefoxitin (FOX) 30 19 22 
Ciprofloxacin 
(CIP) 
5 22 26 
Streptomycin 
(STR) 
10 15 16 
Tetracycline 
(TET) 






     






































































           
Figure 5. Normalised curves of the antibiotics used on the E. coli study population using the NRI method 











































      
Figure 6. Normalised curves of the antibiotic cefotaxime used on the E. coli population using the NRI method 









































3.4 Prevalence of ESBL/AmpC producing E. coli 
Isolates that were resistant to cefotaxime, cefpodoxime or cefoxitin from the antibiotic 
susceptibility testing were suspected to be ESBL/AmpC producers. In total, 31 out of 104 
isolates were presumptive ESBL/AmpC producing E. coli. These were tested using the double 
diffusion test for the presence of an ESBL/AmpC phenotype. All 31 isolates were confirmed 
to be AmpC producers and none of the isolates displayed the ESBL phenotype. Detailed results 
are reported in Appendix D and summarised in Table 9. Overall prevalence of AmpC 
producing E. coli was 30% (31/104) (95% CI 21% - 40%). Farm VCF77 had the highest 
number of AmpC producing isolates. No isolates were positive for AmpC from farm VCF80 
(Table 9).  
At the calf level, 25% (10/40) (95% CI 13% - 41%) of calves were positive for AmpC 
producing E. coli. (Figure 7). 




Total number of isolates 
 
Number of isolates showing an 
AmpC phenotype (%) 
 
VCF77 27 12 (44) 
VCF79 31 11 (35) 
VCF80 20 0 (0) 
VCF89 26 8 (31) 








Figure 7. Number of calves harbouring isolates that showed various resistance phenotypes 
from the 4 farms. 
All 31 confirmed AmpC producers were further analysed using Multiplex and Promoter PCR 
to determine whether the AmpC production was chromosomal or plasmid mediated. Notably, 
all 31 were chromosomal mediated. 
3.5 AmpC sequence results 
The promoter region from the ampC gene of all 31 AmpC positive isolates, was sequenced, to 
determine whether there were mutations in the promoter and attenuator regions. The sequence 
results were analysed and compared with that of E. coli ATCC 25922 wild type that expresses 
low levels of AmpC and thus has negative AmpC phenotype. The functional elements, which 
are the -35 box, -10 box and the attenuator regions of the reference wild type, were compared 
to the isolates. Nucleotide changes (mutations) were observed in 28/31 isolates at position -42, 
-18, -1 and +58 (Figure 8). The same base change was present in all 28 isolates. The sequence 
files for the other three isolates was unable to be analysed due to their chromatograms being 







                                                                                                                    
                                                                    Box-35                                                 Box-10 
                          5'                 -42                                                           -18                                           -1 
ATCC 25922 : CTGCTATCCTGACAGTTGTCACGCTGATTGGTGTCGTTACAATCTAACGCATCGCCAATG 
CE0002C : - - - - - - - - - T - - - - - - - - - - - - - - - - - - - - - - - - - - - A - - - - - - - - - - - - - - - - - - -T - - - 
                                                                                                                                                     Gene start (start codon) 
                        +11                               Attenuator region                                                                 +58                     3' 
ATCC 25922   : TAAA TCCGGCCCGCCTATGGCGGGCCGTTTTGTATGGAAACCAGACCTATGTTCA 
CE0002C : - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -T - - - - - - - - - 
Figure 8. Nucleotide sequence of the ampC gene showing the promoter region (box -35, box -10), the attenuator region and the nucleotide change 






3.6 Phylogrouping results 
A total of 57 resistant E. coli isolates were phylotyped  using the Clermont method (Clermont 
et al., 2013). Phylotyping results are reported in Appendix E and summarised in Table 10. 
Results showed that E. coli isolates were distributed among phylogroup B1, C and D. None of 
the resistant isolates belonged to phylogroup A, B2, E or F. Two isolates were unassigned 
according to Clermont et al. (2013) 
Table 9. Distribution of E. coli phylogroups among the resistant and the susceptible E. coli 
isolates 






Total resistant isolates 
(%) 
B1 10 4 14 (25) 
C 19 34* 37 (65) 
D  0 4 4 (7) 
Unknown 2 0 2 (4) 
Total 31 42 57 
*Combined with AmpC positive isolates that were co-resistant with tetracycline  
3.7 Whole genome sequence results 
Twelve E. coli isolates displaying various antimicrobial resistance phenotypes were selected 
for whole genome sequencing to explore their genetic relatedness and diversity. The whole 
genome sequence data were used to determine sequence type (ST), antimicrobial resistance 
and virulence genes. Most of the isolates belonged to ST88 (8/12) with the remaining four 
belonging to ST10 (2/12) and ST69 (2/12). The antimicrobial resistance genotype was 
concordant with the phenotypic results.  However, some additional antimicrobial resistance 






sulphonamides and qacEdelta for quaternary ammonium were detected. These were not tested 
for phenotypically. Noticeably no plasmid mediated AmpC beta lactamase and ESBL genes 
were found, agreeing with the phenotypic results. The most common virulence genes found for 
adhesion were fimA (encoding type 1 fimbrae protein) found in 11/12 isolates, followed by 
afaA (encoding afimbrial adhesin transcriptional regulator) found in 8/12 isolates. The most 
prevalent virulence genes found affecting iron uptake were, irp1 and irp2 (encoding iron 
regulatory protein 1 and 2) found in 10/12 isolates and iroN (encoding a siderophore receptor) 
found in 6/12 isolates. In addition, virulence genes affecting outer membrane protein were also 
found, with ompA being found in all the 12 isolates. Virulence genes conferring an increased 
survival in serum kpsM were detected in 2/12 isolates. The summarized genomic characteristics 
of the 12 isolates are reported in Table 11. The virulence factors, as well as phenotype of the 
resistance genes, are reported in Appendix F and G respectively. 
The genetic relatedness of these 12 isolates was further investigated using a core SNP approach, 






Table 10. Genomic characteristic of the 12 E. coli isolates 
Farm ID Isolate ID Genome 
size (Mb) 









VCF77 CE0007a 5.16 50.8 148 69 afaA, fimA, kpsD, 
kpsM, ompA,  




VCF77 CE0008b 5.05 52.7 221 10  fimA, fyuA, irp1, 




VCF77 CE0009b 5.22 52.2 467 69 afaA, fimA, iucD, 
kpsD, kpsM, ompA 
aadA1, aph(3”)-1b, 
aph(3’)-1a, aph(6)-1d, 
blaEC- 8 , catA1, dfrA1, 
sul1, sul2, qacEdelta1, 
tet(B) 
STR, TET 
VCF80 CE0011b 5.04 52.1 171 10 fimA, fyuA, iroN, 
irp1, irp2, ompA, pap 








VCF80 CE0014b 5.16 51.1 117 88 afaA, fimA, fyuA, 
iroN, irp1, irp2 
ompA, pap 
aph(3”)-1b, aph(3’)-
1a, aph(6)-1d, blaEC- 13 




VCF80 CE0015a 5.17 50.7 95 88 afaA, fimA, fyuA, 
irp1, irp2, ompA, pap 
aph(3”)-1b, aph(3’)-
1a, aph(6)-1d, blaEC- 13 




VCF89 CE0021a 5.22 51.6 164 88 afaA, fyuA, irp1, irp2, 
ompA 





CE0026a 5.15 50.6 177 88 afaA, fimA, fyuA, 
iroN, irp1, irp2, 
ompA, pap 
aph(3”)-1b, aph(3’)-
1a, aph(6)-1d, blaEC- 13 
, blaTEM-1, sul2, tet(B) 
AmpC3, TET 
CE0026f 5.24 50.9 117 88 fimA, fyuA, iroN, 
irp1, ompA 








VCF89 CE0027c 5.23 51.1 170 88 fimA, fyuA, iroN, 
irp1, irp2, ompA 
blaEC- 13, blaTEM-40, 
tet(A) 
AmpC, TET 
VCF79 CE0032f 5.23 50.7 97 88 afaA, fimA, fyuA, 
iroN, irp1, irp2, 
ompA 
blaEC- 13, blaTEM-40, 
tet(A) 
AmpC, TET 
VCF79 CE0033c 5.23 51.1 106 88 afaA, fimA, fyuA, 
iroN, irp1, irp2, 
ompA 














Figure 9. Neighbour joining phylogeny tree of the 12 E. coli isolates generated using 141221 core SNPs and annotated with the farm ID, sequence 



































4 Discussion  
This study aimed to investigate the prevalence of ESBL and AmpC producing E. coli isolated 
from recto-anal mucosal swabs (RAMS) from waste milk fed dairy calves. Using both culture 
dependent isolation methods and whole genome sequencing, the study also aimed to 
phenotypically and genotypically characterise ESBL and AmpC producing isolates. The 
prevalence of AmpC producing E. coli at the calf level was 25% (10/40) (95% CI 13%-41%) 
and at the isolate level was 30% (31/104) (95% CI 21%-40%). None of the isolates displayed 
an ESBL phenotype.  
The AmpC prevalence was lower than previous studies conducted overseas from waste milk 
fed dairy calves. A study conducted in the Czech Republic from 13 dairy calves with 
documented antimicrobial usage including cefoperazone and cefquinome, a 3rd and 4th  
generation cephalosporin respectively, reported all 13 calves shedding cefotaxime-resistant 
Escherichia coli  with  94% (82/87) of E. coli isolates displaying an AmpC phenotype and none 
displaying an ESBL phenotype (Manga et al., 2019). Another study from the United Kingdom  
(UK) reported an ESBL/AmpC prevalence of 75% (12/16 ) E. coli isolates from waste milk 
fed dairy calves (Randall et al., 2014). Another UK study conducted by Brunton et al. (2014) 
reported a prevalence of 77% (20/25) of dairy calves shedding cefotaxime resistant E. coli 
isolate in calves that were fed waste milk containing cefquinome a 4th generation 
cephalosporin. In Germany Aust et al. (2013) reported a prevalence of 44% (22/50) of calves 
that shed extended spectrum cephalosporins resistant E. coli (ESC-E) isolates that were fed 
waste milk containing cefoperozone, cefotaxime and cefquinome. A New Zealand based study, 
which compared the prevalence of antibiotic resistant E. coli from waste and non-waste milk 
fed dairy calves across 12 Waikato dairy farms, found no 3rd generation cephalosporin resistant 
E. coli. However, 5.2% (10/191) of E. coli isolates were resistant to tetracycline from that study 
(Jarvis & McDougall, 2016). 
The low prevalence of ESBL/AmpC producing E. coli in both our study and that of the Jarvis 
and McDougall (2016) study could be due to New Zealand dairy farms being low users of 
antibiotics, particularly 3rd and 4th generation cephalosporins (Bryan & Hea, 2017; Compton & 
McDougall, 2014). However, in our study data on antibiotic use in study farms was not 
available, hence it is difficult to determine whether the low prevalence could have been due to 






housing used in pasture-based farming system that is practiced in New Zealand may also be 
associated with low incidences of AMR compared to the intensive farming systems practiced  
in Europe, Asia and the USA which has been hypothesised to have higher incidences of AMR 
(Hillerton et al., 2017; Maron et al., 2013). 
This present study also found that the AmpC producing E. coli isolates were chromosomal 
mediated. The phenotypic and genotypic results also indicated that none of the AmpC 
hyperproducing isolates were multidrug resistant (not resistant to more than three classes of 
antibiotics). This is in line with data presented  by Pitout and Laupland (2008) that show ESBLs 
and plasmid mediated AmpC, but not overexpressed chromosomal mediated AmpC being 
associated with multidrug resistance. This is due to the ability of plasmids picking up different 
resistance genes which could lead to accumulation of various resistant genes and hence 
emergence of multi-drug resistance isolates (Bush, 2018).  
This study also found mutations in the promoter and attenuator region of the ampC gene that 
could influence the hyperproduction of the AmpC. Expression of the chromosomal ampC gene 
is not induced in E. coli when exposed to β-lactams. This is due to lack of the ampR gene that 
suppresses the expression of the ampC gene when the bacterium is not exposed to the inducer 
(β-lactams antibiotics); contrary to other Enterobacteriaceae. However, expression and 
overproduction of AmpC can still occur after mutation in the promoter (-35 box and -10 box) 
or attenuator region (Jacoby, 2009; Philippon et al., 2002). The promoter and the attenuator are 
the functional elements of the ampC gene. They regulate the mRNA transcription, hence any 
change in these regions affects the production of the AmpC enzyme (Jaurin & Grundström, 
1981). Analysis of the Sanger sequence data indicated mutation at positions -42, -18, -1 and 
+58 in the promoter and attenuator region of the ampC gene. The same mutations were evident 
in all isolates. These mutations were the same as those found in E. coli isolates from veal calves 
(Ceccarelli et al., 2019) and clinical E. coli isolates (Caroff et al., 1999; Mulvey et al., 2005; 
Olsson et al., 1982; Tracz et al., 2007). Studies have shown that mutations at positions -42, -18 
and -1 lead to overproduction of the AmpC enzyme by enhancing transcription, while changes 
at the +58 position modifies the attenuator loop structure, thereby increasing the transcription 
process leading to overexpressed AmpC enzyme (Caroff et al., 1999). In addition, studies 
suggest that  mutations at the -35 box are the most important for increased transcription while 







In this study, 18/104 E. coli isolates were co-resistance to tetracycline and streptomycin from 
12/40 calves. This was in line with the results reported  in previous studies which reported high 
co-resistance between tetracycline and streptomycin in E .coli isolates from dairy farms, 
despite these antibiotics not being used on the farm (Kyselková et al., 2015; Maynou et al., 
2017a; Maynou et al., 2017b). Kyselková et al. (2015) hypothesised  that these resistant 
bacteria emerged due to the mobilization and transfer of resistant genes from bacteria or genes 
found in the farm environment to fecal derived isolates. Similarly, a study by Srinivasan et al. 
(2008) detected  co-resistance between tetracycline and streptomycin in E. coli isolates from 
dairy farm soil suggesting there could be clonal spread of tetracycline and aminoglycoside 
resistant E. coli or horizontal gene transfer from dairy cattle to the soil or vice versa. However, 
no sequencing of the isolates or their plasmids were done to support this hypothesis. In our 
study we did not have information on tetracycline or streptomycin use on the farms. However, 
tetracycline and aminoglycosides are the next commonly used antibiotics after the penicillins 
in New Zealand dairy farms (Bryan & Hea, 2017; McDougall et al., 2018). None of the isolates 
were resistant to ciprofloxacin. This could be due to ciprofloxacin being rarely used in dairy 
farms in New Zealand (Bryan & Hea, 2017). However, this antibiotic was included in the 
susceptibility testing as it is a critically important antibiotic, according to the classification by 
WHO (2019) and NZVA (2018).  
In this present study, bacterial resistance to antibiotics was investigated using the 
EUCAST/CLSI clinical breakpoints and the ECOFFs generated by the NRI methods. This 
approach was chosen because NRI Epidemiological Cut-Off values determine whether a 
collection of bacterial isolates has a non-wild type (less susceptible) or wild type (fully 
susceptible) phenotype, in contrast to determining the likelihood of treatment failure as is the 
case with the clinical breakpoints. Results of the resistance profiles were close between these 
two methods; for example, tetracycline resistance was 39% (41/104 E. coli isolates) and 41% 
(43/104 E. coli isolates) using EUCAST/CLSI and NRI methods respectively. However, for 
cefotaxime, a higher percentage of non-wildtype isolates were noted but none of the isolates 
were classified as cefotaxime resistant according to the EUCAST/CLSI breakpoints. This could 
be because the cefotaxime breakpoints are based on human clinical isolates which are different 
from veterinary isolates due to their difference in physiology, pharmacokinetics and 
pharmacodynamic between human and livestock hence underestimation of the resistance rate.  
A study in Portugal that assessed antibiotic resistance in E. coli and Salmonella in wild 






generally lower than the EUCAST/CLSI breakpoints (Dias et al., 2015). The results were 
contrary to ours, NRI ECOFFs were higher than the EUCAST/CLSI breakpoints, this could be 
due to E. coli isolates from calves being exposed to more selection pressure of antibiotics, 
biocides and disinfectants compared with the isolates from wild ungulates whose exposure is 
limited.  Another study in Scotland and Norway that investigated E. coli and S. aureus 
resistance in sheep, using both EUCAST/CLSI breakpoints and NRI ECOFFs, found 
disparities between the two methods with the later able to pick up non-wild type isolates that 
were missed by the EUACAST/CLSI method (Silva et al., 2020). This highlights the 
importance of developing host-species specific ECOFFs. 
Phylogenetic analysis showed that the E. coli isolates were distributed among groups B1, C 
and D, with none of the resistant isolates belonging to A, B2, E and F. Phylogrouping of E. coli 
can be achieved through the sequencing of four genes (chuA, yjaA , TspE4.C2 and arpA) by 
using the Clermont method grouping the E. coli into 7 groups A, B1, B2, C, D, E and F 
(Clermont et al., 2013). The basis is that the genomic structure of E. coli isolates that belong to 
a particular phylogroup are not randomly distributed, but rather are associated with a common 
source or sources. Therefore it is important to phylogenetically group E. coli to provide a better 
understanding of their population and potential disease causing abilities (Tenaillon et al., 2010). 
Due to time constraints, only resistant isolates (n = 57) were phylotyped using the Clermont 
quadruplex PCR method. Phylogroup C was the most common 65% (37/57), followed by B1 
25% (14/57). Most AmpC producing isolates belonged to phylogroup C (19), followed by B1 
(10). Similar results were observed among tetracycline and/or streptomycin resistant isolates 
with most isolates belonging to phylogroup C (34) and (4) to B1. Our results were different 
from previous studies, that used non-selective media, found that phylogroup A and B1 were 
the most common in healthy and diarrheic calves respectively (Barzan et al., 2017; Coura et 
al., 2017). In the study by Barzan et al. (2017) B1 was the second most abundant phylogroup, 
as found in our study. Our results also indicate that most of the isolates were commensal 
(phylogroup C and B1) while only four isolates belonged to phylogroup D, which is commonly 
associated with extraintestinal characteristics. In addition, two isolates could not be assigned 
to any group according to the Clermont method, this could be due to the strain being extremely 
rare, or due to having variable gene content as a result of gene loss which is common in E. coli     
(Touchon et al., 2009). It should be noted that most of the B1 and D isolates were from calves 







Whole genome sequencing has become a gold standard in the surveillance, typing and 
diagnosis of pathogens. It allows comparisons between the phenotypic and genotypic 
characteristics of a pathogen and how different genes associate with each other as well as 
determining transmission pathways (Awosile et al., 2020). In this study, using the 7-allele 
house-keeping genes (adk, fumC, gryB, icd, mdh, purA and recA), three sequence types were 
observed with ST88 being the most common. Various studies have reported ST88 being 
common in calves and it has been associated with an enterotoxigenic E. coli (ETEC) pathotype 
and antimicrobial resistance (Awosile et al., 2020; Haenni et al., 2014a). Two isolates belonged 
to ST69. Studies have demonstrated that ST69 display an extra-intestinal pathogenic E. coli 
(EXPEC) pathotype associated with urinary tract infections (UTI) in humans, and are mostly 
phylogroup D (Denamur et al., 2020; Ramchandani et al., 2005). In our study both isolates 
belonged to phylogroup D which was concordant with the findings of other studies. Clinically 
significant virulence genes, e.g. those associated with Shiga toxins were not found, but afaA, 
espP, irp, fyuA, pap and other genes associated with EXPEC were present (Bélanger et al., 
2011; Dezfulian et al., 2003). 
The phenotypic resistance results were concordant with the genotypic results. In addition, 
further resistance genes for trimethoprim, sulfonamides and chloramphenicol were found that 
were not tested phenotypically, which suggests that the tetracycline and streptomycin 
resistance isolates are multidrug resistance. In addition, qacEdelta genes coding for quaternary 
ammonium were detected. Quaternary ammonium products are used as disinfectants in dairy 
farms. However, they are under critical review due to their association with AMR (Davies & 
Wales, 2019; Hegstad et al., 2010). We did not have information on the use of antibiotics, from 
the study farms, however sulfonamide use has been reported in dairy farms in New Zealand 
while chloramphenicol and trimethoprim are rarely used (Bryan & Hea, 2017). In this case 
these resistance genes may be linked (found on the same plasmid) to the tet genes, where the 
use of tetracycline may select for both the tet genes and other resistance genes. This shows the 
importance of whole genome sequencing providing genetic information that is not readily 
available using phenotypic methods.  
Analysis of core genome SNP profiles also demonstrated the phylogenetic relationship 
between isolates. It was observed that isolates were clustered by resistance phenotype, 
sequence type and phylogroups, but not by farm. Noticeably isolates CE0026f, CE0027c, 






resistant phenotype even though they were from different farms. This indicated that there may 
be clonal spread between farms VCF79 and VCF89 which where about 15 kilometers apart.  
Results from a Dutch study indicated that clonal spread of E. coli may have occurred between 
dairy farms in the Netherlands which received calves from Dutch farms and other European 
countries. Analysis revealed that the source was from one of the current receiving farms that 
was not thoroughly disinfected prior to receiving of the new batch of calves that distributed the 
calves to other farms (Hordijk et al., 2013a). Using WGS Findlay et al. (2020) also reported  
clonal spreads of E. coli isolates between dairy farms in a range of 1500 square kilometers. 
Isolates CE0007a and CE0009b from the same farm VCF77 were observed to be distinct from 
the rest of the isolates but showed that transmission between calves within the farm may have 
occurred.  
5 Limitations of the study 
This study investigated waste-milk fed calves only, therefore associations between the use of 
waste milk and the presence of antibiotic resistance bacteria could not be made. In addition, 
we did not have on-farm antibiotic use data to make any conclusions on the presence of 
antimicrobial resistant E. coli. Furthermore, there was sampling bias in the selection of farms 
and calves for screening of E. coli as well as the selection of isolates for the whole genome 
sequencing. Lastly the study sample size was inadequate to generalize results as a 
representative of all farms that use waste milk in New Zealand.  Nevertheless, it’s a starting 
point in providing information about AMR in farms that use waste milk. 
6 Recommendations 
There is lack of data on ESBL/AmpC producing E. coli in dairy calves in New Zealand, 
therefore, we recommend further epidemiological studies to be  carried out across New Zealand 
to determine the prevalence AMR in both waste milk fed calves and non-waste milk fed calves. 
We also recommend surveillance data on the use of antibiotics in dairy farms. Having up to 
date information on how antibiotics are used will provide an understanding on how antibiotic 








7 Conclusion  
This study has taken the first step in characterising ESBL/AmpC producing E. coli in waste 
milk fed dairy calves from the Canterbury region, New Zealand. Our results indicate the 
presence of AmpC hyperproducing E. coli in calves but not plasmid mediated AmpC or ESBLs. 
The results also indicated the presence of other resistance phenotypes; tetracycline and 
streptomycin. Whole genome sequencing of selected resistant isolates provided some genomic 
context on the additional resistance genes displayed by the tetracycline and streptomycin 
resistant isolates making them multidrug resistance but not AmpC positive isolates. Whole 
genome sequence also revealed clonal transmission of E. coli within farm and between farms. 
Further investigations are required to determine whether these antibiotic resistance E. coli are 
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Shed type Shed 
animal 
count 






77 VCF77 2014-9-11 Dairy only 950 650 Open 22 earth straw bore spread 
Open 25 earth straw 
Open 80 earth straw 
80 VCF80 2014-9-15 Dairy only 1000 1000 Open 8 earth woodchips bore spread 
Open 9 earth woodchips 
Open 10 earth woodchips 
89 VCF89 2014-9-17 Dairy only 1700 1700 Conversion 5 earth woodchips city spread 
open 40 metal stone woodchips 






79 VCF79 2014-9-15 Dairy only 1100 1100 
 
Open 7 slats straw bore spread 
open 8 metal stone sawdust 
Conversion 11 metal stone sawdust 
 
Appendix B. Table of detailed information of the dairy calves from Canterbury region and their metadata 
Farm 
sample ID 
Calf ID Calf sample ID Date sampled  Age Sex Breed Class 
VCF77 1128 VC1128 2014-09-11 
 
Young1 Male Friesian Bobby 
VCF77 1129 VC1129 2014-09-11 
 
Young Male Friesian Bobby 
VCF77 1130 VC1130 2014-09-11 
 






VCF77 1131 VC1131 2014-09-11 
 
Young Male Friesian Bobby 
VCF77 1132 VC1132 2014-09-11 
 
Young Male Friesian Bobby 
VCF77 1133 VC1133 2014-09-11 
 
Young Female Friesian Replacement 
VCF77 1134 VC1134 2014-09-11 
 
Young Female Friesian Replacement 
VCF77 1135 VC1135 2014-09-11 
 
Young Female Friesian Replacement 
VCF77 1136 VC1136 2014-09-11 
 
Young Female Friesian Replacement 







VCF80 1173 VC1173 2014-09-15 
 
Young Male Friesian Bobby 
VCF80 1174 VC1174 2014-09-15 
 
Young Male Friesian Bobby 
VCF80 1175 VC1175 2014-09-15 
 
Young Female Friesian Bobby 
VCF80 1176 VC1176 2014-09-15 
 
Young Male Friesian Bobby 
VCF80 1177 VC1177 2014-09-15 
 
Young Male Friesian Bobby 
VCF80 1178 VC1178 2014-09-15 
 






VCF80 1179 VC1179 2014-09-15 
 
Young Female Friesian Replacement 
VCF80 1180 VC1180 2014-09-15 
 
Young Female Friesian Replacement 
VCF80 1181 VC1181 2014-09-15 
 
Young Female Friesian Replacement 
VCF80 1182 VC1182 2014-09-15 
 
Young Female Friesian Replacement 
VCF89 1299 VC1299 2014-09-17 
 
Young Male Friesian Beef 
VCF89 1300 VC1300 2014-09-17 
 
Young Male Friesian Beef 







VCF89 1302 VC1302 2014-09-17 
 
Young Male Friesian Beef 
VCF89 1303 VC1303 2014-09-17 
 
Young Male Friesian Beef 
VCF89 1304 VC1304 2014-09-17 
 
Young Female Friesian Replacement 
VCF89 1305 VC1305 2014-09-17 
 
Young Male Friesian Beef 
VCF89 1306 VC1306 2014-09-17 
 
Young Male Friesian/Jersey mix Bobby 
VCF89 1307 VC1307 2014-09-17 
 






VCF89 1308 VC1308 2014-09-17 
 
Young Female Holstein Beef 
VCF79 1158 VC1158 2014-09-15 
 
Young Male Friesian/Jersey mix Bobby 
VCF79 1159 VC1159 2014-09-15 
 
Young Male Friesian/Jersey mix Bobby 
VCF79 1160 VC1160 2014-09-15 
 
Young Male Friesian/Jersey mix Bobby 
VCF79 1161 VC1161 2014-09-15 
 
Young Male Friesian/Jersey mix Bobby 
VCF79 1162 VC1162 2014-09-15 
 
Young Male Friesian/Jersey mix Bobby 







VCF79 1164 VC1164 2014-09-15 
 
Young Male Friesian/Jersey mix Replacement 
VCF79 1165 VC1165 2014-09-15 
 
Young Male Friesian/Jersey mix Replacement 
VCF79 1166 VC1166 2014-09-15 
 
Young Male Jersey Replacement 
VCF79 1167 VC1167 2014-09-15 
 
Young Male Jersey Replacement 









Appendix C. Results of screening, identification and antibiotic zone diameters of the isolates recovered from waste milk fed dairy calves from 
four dairy farms. 






              ZONE DIAMETER OF ANTIMICROBIALS (MM) 
CTX CPD FOX CIP STR TET 







CE0002a E. coli 26.3 25.4 22.5 33.0 17.8 17.4 
CE0002b E. coli 27.2 26.4 20.9 29.1 16.0 19.0 
CE0002c E. coli 18.4 7.6* 13.9* 28.0 17.5 18.0 
CE0002d E. coli 23.8 8.2* 13.2* 30.2 17.6 19.3 
CE0002e E. coli 23.6 8.2* 13.5* 30.2 18.6 19.6 
CE0002f E. coli 23.5 9.1* 13.2* 29.6 18.7 18.1 
VCF77 VC1130/CE0003 CE0003a E. coli 30.1 20.2 23.6 28.6 17.4 19.6 








VC1131/CE0004 CE0004a E. coli 29.9 25.1 27.0 29.4 15.9 15.3 
CE0004b E. coli 30.6 25.3 23.3 32.5 17.4 18.5 
CE0004c E. coli 22.6 7.3* 12.7* 32.6 18.2 16.2 
CE0004d E. coli 24.9 8.6* 12.6* 30.8 17.4 18.5 
CE0004e E. coli 23.9 9.7* 12.9* 32.2 18.1 17.2 
CE0004f E. coli 22.7 9.1* 13.1* 31.6 18.0 16.5 
VCF77 VC1132/CE0005 CE0005a E. coli 30.4 24.1 25.8 32.2 17.1 17.0 
CE0005b K. pneumoniae 35.0 27.6 25.6 30.6 17.9 21.7 
 
VCF77 
VC1133/CE0006 CE0006a E. coli 33.4 25.5 23.3 32.8 18.7 18.9 
CE0006b K. pneumoniae 32.5 28.3 24.2 32.4 18.2 19.3 
CE0006c E. coli 25.0 7.1* 12.3* 34.6 19.5 19.6 
CE0006d E. coli 23.4 7.7* 11.7* 34.7 19.1 18.7 






VCF77 CE0007b E. coli 31.6 25.8 23.0 33.2 10.7* 6.1* 
CE0007c E. coli 21.9 7.7* 11.8* 34.6 19.3 18.0 
CE0007d E. coli 22.0 7.0* 11.6* 31.8 19.1 17.3 
VCF77 VC1135/CE0008 CE0008a E. coli 32.2 26.4 25.5 32.2 18.0 20.1 
CE0008b E. coli 36.6 28.4 26.2 39.6 7.9* 6.0* 
VCF77 VC1136/CE0009 CE0009a E. coli 35.2 27.8 27.0 34.0 18.1 18.9 
CE0009b E. coli 32.8 27.7 24.6 33.1 6.2* 6.0* 
VCF77 VC1137/CE0010 CE0010a E. coli 36.2 29.4 25.5 39.8 9.0* 6.0* 
CE0010b K. pneumoniae 35.4 30.6 23.2 29.7 19.6 19.9 
VCF80 VC1173/CE0011 CE0011a E. coli 36.4 29.6 25.6 36.2 6.0* 6.0* 
CE0011b E. coli 36.4 30.4 26.4 37.2 6.0* 6.0* 
VCF80 VC1174/CE0012 CE0012a E. coli 32.6 27.6 25.7 36.0 6.0* 6.0* 






VCF80 VC1175/CE0013 CE0013a E. coli 33.0 25.3 26.2 35.2 9.2* 6.0* 
CE0013b E. coli 36.6 26.2 26.5 37.4 6.0* 6.0* 
VCF80 VC1176/CE0014 CE0014a E. coli 35.2 28.6 26.6 39.0 17.5 20.2 
CE0014b E. coli 32.8 26.6 26.6 37.2 6.0* 6.0* 
VCF80 VC1177/CE0015 CE0015a E. coli 32.6 26.8 25.2 33.2 6.0* 6.0* 
CE0015b E. coli 32.8 27.0 27.5 32.6 16.8 6.0* 
VCF80 VC1178/CE0016 CE0016a E. coli 35.3 30.0 26.4 34.8 16.6 22.5 
CE0016b E. coli 36.2 25.3 23.1 32.0 16.0 18.7 
VCF80 VC1179/CE0017 CE0017a E. coli 34.0 28.8 26.4 37.2 6.0* 6.0* 
CE0017b E. coli 35.0 28.6 26.4 36.2 6.1* 6.0* 
VCF80 VC1180/CE0018 CE0018a E. coli 37.3 30.2 24.7 39.6 16.8 20.6 
CE0018b E. coli 33.0 25.9 27.9 33.7 17.6 20.8 






CE0019b E. coli 34.4 28.2 26.4 30.5 15.7 19.9 
VCF80 VC1182/CE0020 CE0020a E. coli 34.5 28.4 26.0 30.7 16.6 21.0 
CE0020b E. coli 31.8 28.8 27.3 34.6 16.2 18.2 
VCF89 VC1299/CE0021 CE0021a E. coli 36.0 28.6 26.2 34.8 6.0* 6.0* 
CE0021b E. coli 36.2 28.8 25.6 36.4 6.0* 6.0* 
VCF89 VC1300/CE0022 CE0022a E. coli 34.4 26.4 28.0 34.7 6.0* 19.7 
CE0022b E. coli 35.2 26.4 27.5 33.7 18.2 20.4 
VCF89 VC1301/CE0023 CE0023a E. coli 32.7 26.3 26.8 32.9 17.6 21.3 
CE0023b E. coli 33.9 25.8 25.5 35.5 19.3 20.2 
VCF89 VC1302/CE0024 CE0024a E. coli 35.6 29.1 25.3 39.7 11.8 6.0* 
CE0024b E. coli 35.7 28.2 25.6 38.9 11.2 6.0* 
VCF89 VC1303/CE0025 CE0025a E. coli 32.8 29.1 26.3 38.0 17.7 19.2 






VCF89 VC1304/CE0026 CE0026a E. coli 32.9 25.5 25.7 36.4 10.1* 6.0* 
CE0026b E. coli 34.3 28.6 25.0 38.4 17.8 21.3 
CE0026c E. coli 24.0 6.1* 13.6* 32.4 18.4 6.0* 
CE0026d E. coli 24.4 6.2* 13.8* 34.3 18.0 6.1* 
CE0026e E. coli 24.6 6.2* 14.0* 34.4 18.3 6.1* 
CE0026f E. coli 24.2 6.4* 14.5* 34.6 18.4 6.2* 
VCF89 VC1305/CE0027 CE0027a E. coli 34.7 27.2 25.0 36.3 11.2 6.0* 
CE0027b E. coli 33.4 28.2 25.0 33.2 14.1 12.2* 
CE0027c E. coli 27.8 13.0* 17.9* 32.0 15.4 6.0* 
CE0027d E. coli 26.4 13.0* 17.2* 31.2 15.1 6.0* 
CE0027e E. coli 24.2 6.0* 14.2* 32.4 18.3 6.0* 
CE0027f E. coli 23.4 6.0* 14.2* 32.2 18.5 6.0* 






CE0028b E. coli 37.0 30.0 25.3 39.6 20.8 21.7 
VCF89 VC1307/CE0029 CE0029a E. coli 35.2 30.2 26.8 35.6 18.2 23.7 
CE0029b K. pneumoniae 36.4 32.8 27.1 32.5 18.6 21.1 
VCF89 VC1308/CE0030 CE0030a E. coli 32.0 29.2 24.6 36.8 18.0 20.0 
CE0030b K. pneumoniae 32.7 31.0 27.7 34.4 19.0 21.4 
VCF79 VC1158/CE0031 CE0031a E. coli 35.0 30.0 27.0 40.0 19.4 21.0 
CE0031b E. coli 35.4 30.0 26.3 37.0 18.4 21.4 
VCF79 VC1159/CE0032 CE0032a E. coli 31.4 25.1 25.6 36.7 18.9 19.0 
CE0032b E. coli 31.3 28.2 26.7 35.0 18.2 19.3 
CE0032c E. coli 24.0 6.1* 14.7* 34.4 18.5 6.0* 
CE0032d E. coli 25.6 6.1* 15.0* 35.0 19.5 6.0* 
CE0032e E. coli 24.4 6.1* 14.8* 33.3 19.0 6.0* 






VCF79 VC1160/CE0033 CE0033a E. coli 32.3 23.7 22.6 36.1 20.3 20.9 
CE0033b E. coli 36.0 28.6 27.7 40.0 21.4 6.0* 
CE0033c E. coli 26.1 6.2* 14.6* 33.5 18.8 6.0* 
CE0033d E. coli 25.7 6.0* 14.2* 32.8 18.7 6.0* 
CE0033e E. coli 24.2 6.1* 14.6* 33.8 18.1 6.0* 
CE0033f E. coli 24.2 6.2* 14.7* 30.5 18.1 6.0* 
VCF79 VC1161/CE0034 CE0034a E. coli 32.7 28.6 26.8 34.6 20.8 20.8 





CE0035a E. coli 34.2 30.2 26.4 33.5 17.1 22.0 
CE0035b E. coli 34.0 28.0 26.4 33.0 16.5 22.6 
VCF79 VC1163/CE0036 CE0036a E. coli 36.0 27.6 25.3 36.9 18.6 20.8 
CE0036b E. coli 38.4 32.8 25.4 37.2 20.1 21.5 






CE0037b E. coli 35.2 26.6 26.5 38.0 18.5 21.3 
VCF79 VC1165/CE0038 CE0038a E. coli 35.4 28.9 22.8 35.5 17.6 20.6 
CE0038b E. coli 36.0 29.6 27.2 38.0 19.0 20.9 
VCF79 VC1166/CE0039 CE0039a E. coli 32.7 25.9 23.6 36.0 18.5 20.0 
CE0039b E. coli 33.3 28.1 26.0 34.9 18.7 24.7 
CE0039e E. Coli 24.7 6.0* 13.1* 35.8 18.9 19.7 
VCF79 VC1167/CE0040 CE0040a E. coli 32.5 27.1 24.4 37.2 19.4 21.4 
CE0040b E. coli 34.6 28.9 27.2 38.2 18.5 20.4 
CE0040c E. coli 24.2 6.0* 13.6* 38.0 18.9 19.7 
CE0040e E. coli 24.6 6.2* 13.2* 38.2 18.8 19.8 
a: MacConkey, b: MacConkey, c: MacConkey + CTX, d: MacConkey + CTX, e: MacConkey + CAZ, f: MacConkey + CAZ 
CTX: cefotaxime, CPD: cefpodoxime, FOX: cefoxitin, STR: streptomycin, CIP: ciprofloxacin, TET: tetracycline, CAZ: ceftazidime 


























ESBL CTX1 ESBL CAZ2 AmpC3 









































































































































































































































































































































































































































































































































































































































































































































































































































































































1 ESBL CTX = clavulanate double disc synergy test with cefotaxime, 2 ESBL CAZ = clavulanate double disc synergy test with ceftazidime, 
3 AmpC = AmpC double disc diffusion test, Z = zone 
 
Appendix E. Distribution of E. coli phylogroups among the resistant and the susceptible E. coli isolates 












CE0002c   +    -    -    +   - B1 AmpC1,  
CE0002d   +    -    -    +   - B1 AmpC 
CE0002e   +    -    -    +   - B1 AmpC 






CE0004c    +    -    -    +   - B1 AmpC 
CE0004d    +    -    -    +   - B1 AmpC 
CE0004e    +    -    -    +   - B1 AmpC 
CE0004f    +    -    -    +   - B1 AmpC 
CE0006c     -    -    -    +   - Unknown AmpC 
CE0006d     -    -    -    +   - Unknown AmpC 
CE0007a    +    -   +    -   - C STR2, TET3 
CE0007b    +    +   -    -   - D STR, TET 
CE0007c    +     -   -    +   - B1 AmpC 
CE0007d    +     -   -    +   - B1 AmpC 
CE0008b    +     +   -    -   - D STR, TET 
CE0009b    +     -   +    -   - C STR, TET 






CE0011a    +     -   +    -   - C STR, TET 
CE0011b    +     -   +    -   - D STR, TET 
CE0012a    +     -    -   +   - B1 STR, TET 
CE0012b    +     -    +   -   - C STR, TET 
CE0013a    +     -    +   -   - C STR, TET 
CE0013b    +     -    +   -   - C STR, TET 
CE0014b    +     -    +   -   - C STR, TET 
CE0015a    +     -    -   +   - B1 STR, TET 
CE0015b    +     -    +   -   - C TET 
CE0017a    +     -    +   -   - C STR, TET 
CE0017b    +     -    +   -   - C STR, TET 
CE0021a    +     -    +   -   - C STR, TET 






CE0022a    +     -    -   +   - B1 STR 
CE0024a    +     -    +   -   - C TET 
CE0024b    +     -    +   -   - C TET 
CE0025b    +     -    +   -   - C TET 
CE0026a    +     -    +   -   - C STR, TET 
CE0026c    +     -    +   -   - C AmpC, TET 
CE0026d    +     -    +   -   - C AmpC, TET 
CE0026e    +     -    +   -   - C AmpC, TET 
CE0026f    +     -    +   -   - C AmpC, TET 
CE0027a    +     -    +   -   - C TET 
CE0027b    +     -    -   +   - B1 TET 
CE0027c    +     -    +   -   - C AmpC, TET 






CE0027e    +     -    +   -   - C AmpC, TET 
CE0027f    +     -    +   -   - C AmpC, TET 
CE0032c    +     -    +   -   - C AmpC, TET 
CE0032d    +     -    +   -   - C AmpC, TET 
CE0032e    +     -    +   -   - C AmpC, TET 
CE0032f    +     -    +   -   - C AmpC, TET 
CE0033b    +     -    +   -   - C TET 
CE0033c    +     -    +   -   - C AmpC, TET 
CE0033d    +     -    +   -   - C AmpC, TET 
CE0033e    +     -    +   -   - C AmpC, TET 
CE0033f    +     -    +   -   - C AmpC, TET 
CE0039e    +     -    +   -   - C AmpC 






CE0040e    +     -    +   -   - C AmpC 






Appendix F. Virulence genes and what they encode for 
Virulence gene description 
afaA Transcriptional regulator 
afaD Afimbrial adhesion 
astA EAST-1 heat stable toxin 
chuA Outer membrane hemin receptor 
espP Extracellular serine protease 
fimA Adhesin  
fyuA Siderophore receptor  
iroN Siderophore receptor protein  
irp2 High molecular weight protein 2 non-
ribosomal peptide synthetase 
iucD Iron uptake 
kpsD Polysialic acid transport protein; group 2 
kpsM Polysialic acid transport protein; group 2 
ompA Outer membrane protein 










Appendix G. Resistance genes and their phenotypic description 
Resistance 
gene 













blaEC-13 Beta-lactamase ampicillin, amoxicillin, cephalosporin 
blaEC-8 Beta-lactamase ampicillin, amoxicillin, cephalosporin 
blaTEM-1 Beta-lactamase ampicillin, amoxicillin, cephalosporin 








sul1, sul2 Dihydropteroate 
synthase 
sulphonamides 





































0 74319 74311 73914 73913 74507 74110 74492 74486 74489 74487 18 87229 
CE0008
b 
74319 0 22 39862 39861 39506 38904 39258 39266 39254 39254 74313 86772 
CE0011
b 
74311 22 0 39856 39855 39500 38898 39252 39260 39248 39248 74305 86776 
CE0014
b 
73914 39862 39856 0 3 5868 3116 7470 7478 7470 7468 73918 86702 
CE0015
a 
73913 39861 39855 3 0 5867 3115 7469 7475 7469 7467 73917 86701 
CE0021
a 









74110 38904 38898 3116 3115 4399 0 6303 6311 6303 6301 74114 86564 
CE0026
f 
74492 39258 39252 7470 7469 6310 6303 0 10 46 44 74494 86964 
CE0027
c 
74486 39266 39260 7478 7475 6318 6311 10 0 54 52 74488 86958 
CE0032
f 
74489 39254 39248 7470 7469 6310 6303 46 54 0 2 74491 86958 
CE0033
c 
74487 39254 39248 7468 7467 6308 6301 44 52 2 0 74489 86960 
CE009b 18 74313 74305 73918 73917 74511 74114 74494 74488 74491 74489 0 87219 
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